Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01978236 |
| Title | Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | GlaxoSmithKline |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA | AUS |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| GSK Investigational Site | Pittsburgh | Pennsylvania | 15232 | United States | Details | |
| GSK Investigational Site | Houston | Texas | 77030 | United States | Details | |
| GSK Investigational Site | North Sydney | New South Wales | 2060 | Australia | Details |